![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Markman Maurie
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.2, Iss.6, 2003-11, pp. : 597-607
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 12, 1997-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 12, 1998-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Expert Opinion on Investigational Drugs, Vol. 7, Iss. 12, 1998-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design, Vol. 14, Iss. 27, 2008-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Current Medicinal Chemistry, Vol. 12, Iss. 19, 2005-09 ,pp. :